Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries

Open Access

Peer-reviewed

Research Article

Thomas M. Harmon ,

* E-mail: tharmon@iavi.org (TMH); anaeveke@iavi.org (AN)

Affiliation International AIDS Vaccine Initiative, New York, NY, United States of America
⨯
Kevin A. Fisher,

Affiliation AVAC, New York, NY, United States of America
⨯
Margaret G. McGlynn,

Affiliation International AIDS Vaccine Initiative, New York, NY, United States of America
⨯
John Stover,

Affiliation Avenir Health, Glastonbury, CT, United States of America
⨯
Mitchell J. Warren,

Affiliation AVAC, New York, NY, United States of America
⨯
Yu Teng,

Affiliation Avenir Health, Glastonbury, CT, United States of America
⨯
Arne Näveke

* E-mail: tharmon@iavi.org (TMH); anaeveke@iavi.org (AN)

Affiliation International AIDS Vaccine Initiative, New York, NY, United States of America
⨯

Reader Comments (0)

HIV vaccines
Is the Subject Area "HIV vaccines" applicable to this article?

Thanks for your feedback.
Vaccine development
Is the Subject Area "Vaccine development" applicable to this article?

Thanks for your feedback.
HIV infections
Is the Subject Area "HIV infections" applicable to this article?

Thanks for your feedback.
AIDS
Is the Subject Area "AIDS" applicable to this article?

Thanks for your feedback.
Cost-effectiveness analysis
Is the Subject Area "Cost-effectiveness analysis" applicable to this article?

Thanks for your feedback.
Booster doses
Is the Subject Area "Booster doses" applicable to this article?

Thanks for your feedback.
Low and middle income countries
Is the Subject Area "Low and middle income countries" applicable to this article?

Thanks for your feedback.
Low income countries
Is the Subject Area "Low income countries" applicable to this article?

Thanks for your feedback.